These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 8414287)
41. Safety and efficacy of an extended-regimen oral contraceptive utilizing continuous low-dose ethinyl estradiol. Anderson FD; Gibbons W; Portman D Contraception; 2006 Mar; 73(3):229-34. PubMed ID: 16472561 [TBL] [Abstract][Full Text] [Related]
42. The European experience: an overview. Gillmer MD Int J Fertil; 1992; 37 Suppl 1():36-46. PubMed ID: 1347519 [No Abstract] [Full Text] [Related]
43. New contraception options. Smith MJ Diabetes Self Manag; 2004; 21(5):20-2, 25. PubMed ID: 15586908 [No Abstract] [Full Text] [Related]
44. Lybrel--a continuous oral contraceptive. Med Lett Drugs Ther; 2007 Jul; 49(1266):61-2. PubMed ID: 17652998 [No Abstract] [Full Text] [Related]
45. Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women. Griffith SG; Dai Y Clin Ther; 2004 Dec; 26(12):2056-65. PubMed ID: 15823769 [TBL] [Abstract][Full Text] [Related]
49. FDA approves new oral contraceptive. FDA Consum; 2003; 37(6):5. PubMed ID: 14983808 [No Abstract] [Full Text] [Related]
50. A clinical study of transdermal contraceptive patch in Thai adolescence women. Piyasirisilp R; Taneepanichskul S J Med Assoc Thai; 2008 Feb; 91(2):137-41. PubMed ID: 18389975 [TBL] [Abstract][Full Text] [Related]
51. Rationale for new oral contraceptive dosing. Williams JK Int J Fertil Womens Med; 2004; 49(1):30-5. PubMed ID: 15038507 [TBL] [Abstract][Full Text] [Related]
52. Safety and efficacy of a new oral contraceptive containing drospirenone. Shulman LP J Reprod Med; 2002 Nov; 47(11 Suppl):981-4. PubMed ID: 12497672 [TBL] [Abstract][Full Text] [Related]
53. [Clinical experiences with a gestodene containing oral contraceptive (femoden)]. Gimes G; Valent S Acta Pharm Hung; 1998 Sep; 68(5):289-93. PubMed ID: 9805815 [TBL] [Abstract][Full Text] [Related]
54. Influence of taranabant, an orally active, highly selective, potent cannabinoid-1 receptor (CB1R) inverse agonist, on ethinyl estradiol and norelgestromin plasma pharmacokinetics. Schwartz JI; Dunbar S; Yuan J; Li S; Miller DL; Rosko K; Johnson-Levonas AO; Lasseter KC; Wagner JA J Clin Pharmacol; 2009 Jan; 49(1):72-9. PubMed ID: 18936284 [TBL] [Abstract][Full Text] [Related]
55. [Immunological studies of the vaginal secretion in women using contraceptive preparations]. Nalbanski B; Stanislavov R Akush Ginekol (Sofiia); 1981; 20(4):337-40. PubMed ID: 7304853 [No Abstract] [Full Text] [Related]
56. Pregnancy and porphyria cutanea tarda. Rajka G Acta Derm Venereol; 1984; 64(5):444-5. PubMed ID: 6208730 [TBL] [Abstract][Full Text] [Related]
57. [Myasthenia and oral contraceptives (a case report)]. Kiehl U Z Arztl Fortbild (Jena); 1984; 78(4):153-4. PubMed ID: 6711038 [No Abstract] [Full Text] [Related]